Astrazeneca Pharmaceuticals
Astrazeneca Pharmaceuticals is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia
Sponsor Acerta Pharma B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Global, Randomized, Modified Double-Blind, Placebo‑Controlled, Study to Evaluate the Efficacy, Immunogenicity, and Safety of IVX-A12, a Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) Virus-Like Particle (VLP) Vaccine in Adults 60 Years of Age and Older.
Sponsor AstraZeneca AB
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma
Sponsor Acerta Pharma B.V.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Astrazeneca Pharmaceuticals?
The 2026-10-09 snapshot links Astrazeneca Pharmaceuticals to 4 distinct CTIS trials. Recorded services include Safety reporting & pharmacovigilance, Laboratory services, PBMC samples analysis. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Astrazeneca Pharmaceuticals?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Astrazeneca Pharmaceuticals conducted?
The linked trials record locations in 13 countries, including France, Poland, Belgium, Germany, Spain. These are trial locations, not confirmed office locations or countries where Astrazeneca Pharmaceuticals delivered services.
What can this page tell me about Astrazeneca Pharmaceuticals's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Astrazeneca Pharmaceuticals. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Astrazeneca Pharmaceuticals LP